Novel CDK8 inhibitor

Novel potent CDK8 inhibitor

Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition

Novel highly potent, selective, permeable CDK8 inhibitor

Novel inhibitor of CDK8

Novel potent and selective inhibitor of CDK8, also modulating CDK19

Potent dual inhibitor of CDK8/19, suppressing phosphorylated STAT1 in various cancer cells

Novel potent and selective dual inhibitor of CDK8 and CDK19

Novel potent CDK8 inhibitor

Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo

Novel potent CDK6 degrader

Potent, ATP-binding site-targeting Cdk4/D1 inhibitor

Novel potent and selective CDK12 inhibitor

Novel selective cdDHQD inhibitor

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel agonist for the vitamin D receptor (VDR)

Novel CD33 pre-mRNA splicing modulator, increasing exon 2 skipping in cellular mRNA pools

Novel CD22 glycan ligand, targeting CD22-expressing B cells, uptaking and enhancing siRNA gene expression knockdown via formation of CD22 glycan ligand-conjugated siRNA

Retinoic acid receptor beta (RARbeta) agonist, overcoming inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cord.

Novel telomerase inhibitor

Novel Caspase-1 inhibitor

Novel MC1R agonist

Novel potent covalent BRD4 degrader, degrading BRD4 in a proteasome- and RNF4-dependent manner without inhibiting RNF4 autoubiquitination activity

Novel inhibitor of the efflux function of ABCG2, selectively reversing ABCG2-mediated MDR in cancer cells in vitro and in vivo

Novel inhibitor of BCL6

Highly Selective Oral Checkpoint Kinase 1 (CHK1) Inhibitor

Inactive analogue of pictilisib to be used as the negative control

Novel dual FLT3/Aurora A inhibitor, overcoming D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells

Novel CCR4 antagonist, enhancing DC activation and homing to the regional lymph node and showing potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment